Daiichi Sankyo and Merck withdrew the I-DXd BLA in ES-SCLC after FDA discussions found phase 2 IDeate-Lung01 data insufficient for accelerated approval.
|Videos|August 9, 2017
Dr. Chiang Discusses Ipilimumab Plus Nivolumab in Small Cell Lung Cancer
Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer.
Advertisement
Anne Chiang, MD, PhD, professor and thoracic oncologist at Yale Cancer Center, discusses ipilimumab (Yervoy) plus nivolumab (Opdivo) in small cell lung cancer (SCLC).
This combination is now included in the National Comprehensive Cancer Network (NCCN) guidelines for this indication, but it not yet FDA approved.
Chiang says that although the lack of approval raises questions as a clinician, the impact of this immunotherapy combination is a tremendous milestone for SCLC.
Advertisement
Related to this article
FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
The addition of the β-catenin pathway inhibitor tegavivint to osimertinib produced deep responses in a phase 1b study in first-line EGFR-mutated NSCLC.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The phase 3 REZILIENT3 trial met its primary end point at a pre-specified interim analysis, with a median PFS of 14.5 months and a 65.0% ORR.
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
FDA Approves Belzutifan Plus Lenvatinib for Advanced ccRCC
4
FDA Grants Priority Review to Perioperative Durvalumab Plus Neoadjuvant Enfortumab Vedotin in MIBC
5